IL144831A0 - USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS - Google Patents

USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Info

Publication number
IL144831A0
IL144831A0 IL14483100A IL14483100A IL144831A0 IL 144831 A0 IL144831 A0 IL 144831A0 IL 14483100 A IL14483100 A IL 14483100A IL 14483100 A IL14483100 A IL 14483100A IL 144831 A0 IL144831 A0 IL 144831A0
Authority
IL
Israel
Prior art keywords
pivs
piv
vectors
protect against
disease caused
Prior art date
Application number
IL14483100A
Other languages
English (en)
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/459,062 external-priority patent/US7250171B1/en
Priority claimed from US09/458,813 external-priority patent/US7314631B1/en
Application filed by Us Health filed Critical Us Health
Publication of IL144831A0 publication Critical patent/IL144831A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14483100A 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS IL144831A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17019599P 1999-12-10 1999-12-10
US09/459,062 US7250171B1 (en) 1997-05-23 1999-12-10 Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US09/458,813 US7314631B1 (en) 1997-05-23 1999-12-10 Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
PCT/US2000/033293 WO2001042445A2 (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Publications (1)

Publication Number Publication Date
IL144831A0 true IL144831A0 (en) 2002-06-30

Family

ID=27389780

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14483100A IL144831A0 (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Country Status (8)

Country Link
EP (1) EP1179054A2 (enExample)
JP (1) JP4795597B2 (enExample)
CN (2) CN102766605A (enExample)
AU (1) AU785148B2 (enExample)
CA (1) CA2362685A1 (enExample)
IL (1) IL144831A0 (enExample)
MX (1) MXPA01008108A (enExample)
WO (1) WO2001042445A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
ATE509097T1 (de) 2001-11-21 2011-05-15 Us Health Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
TWI344991B (en) 2002-02-21 2011-07-11 Medimmune Vaccines Inc Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
AU2003247777B2 (en) 2002-07-01 2008-09-18 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP2007524372A (ja) 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 組換えヒトメタニューモウイルスおよびその使用
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
WO2004113517A2 (en) 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
EP1899483A4 (en) * 2005-05-11 2009-02-11 Univ Wayne State NEW TARGETS FOR THE IDENTIFICATION OF ANTIBIOTICS, NOT SENSITIVE TO ANTIBIOTIC RESISTANCE
US8293517B2 (en) 2005-05-11 2012-10-23 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in Pseudomonas aeruginosa
JP4905649B2 (ja) * 2006-03-08 2012-03-28 国立大学法人 長崎大学 魚用ワクチン、その製造方法、および魚類感染症の予防方法
JP4892296B2 (ja) 2006-08-24 2012-03-07 川崎製薬株式会社 魚類のエドワジェラ症及び連鎖球菌症用ワクチン
US8362203B2 (en) 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
MY173638A (en) 2012-01-24 2020-02-12 Univ Georgia Parainfluenza virus 5 based vaccines
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
CN103773803A (zh) * 2014-01-23 2014-05-07 中国农业科学院特产研究所 表达猪o型口蹄疫病毒vp1蛋白的重组牛副流感病毒载体
EP3630173A1 (en) 2017-05-29 2020-04-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
JP2021528970A (ja) * 2018-06-27 2021-10-28 メディカゴ インコーポレイテッド インフルエンザウイルスヘマグルチニン変異体
EP3844758A1 (en) * 2018-08-28 2021-07-07 Koninklijke Philips N.V. Method for assessing genome alignment basis
BR112021019120A2 (pt) * 2019-03-25 2021-11-30 Baylor College Medicine Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用
CN113999292B (zh) * 2021-10-27 2023-05-26 中国农业大学 靶向呼吸道病毒属病毒的多肽抑制剂
JP2025518078A (ja) 2022-05-25 2025-06-12 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 低減した抗ベクター抗原性を有するワクチン
AU2024380679A1 (en) 2023-11-17 2026-07-02 Sanofi Vaccines US Inc. Trehalose vaccine formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69842165D1 (de) * 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
CA2378661A1 (en) * 1999-07-09 2001-01-18 Alexander C. Schmidt Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Also Published As

Publication number Publication date
CN1347453A (zh) 2002-05-01
JP2003516148A (ja) 2003-05-13
JP4795597B2 (ja) 2011-10-19
AU2073101A (en) 2001-06-18
AU785148B2 (en) 2006-10-05
CN102766605A (zh) 2012-11-07
CA2362685A1 (en) 2001-06-14
MXPA01008108A (es) 2004-11-12
EP1179054A2 (en) 2002-02-13
WO2001042445A2 (en) 2001-06-14
WO2001042445A3 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
AU2001281309A1 (en) The use of c3-c5 monosaccharides to protect keratinous fibers
GR1002767B (el) Αντιπαρασιτικη συνθεση για την θεραπεια και την προστασια των ζωων συντροφιας.
BR9710740A (pt) FÄrmula de vacina polinucleotidica contra as patologias respiratÄrias e de reprodu-Æo de porcos
NO983083D0 (no) Medisinteknisk anordning til forbedring av hudfiksering av permanente katetere og andre transkutane implantater ved redusert infeksjonsfare
ATE236186T1 (de) L-nukleoside zur behandlung des hepatitis-b- und epstein-bar-virus
EP1434873A4 (en) GENOTICIZATION KIT FOR THE DIAGNOSIS OF INFECTION WITH HUMAN PAPILLOMA VIRUS
GB0103133D0 (en) Improvements on or relating to medical imaging
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
DE10084458T1 (de) Absorptionsfähige Gewebe zur Verbesserung der Hautschutzschicht
ID27867A (id) Benda-benda penyerap dapat dibuang yang melekat pada tubuh mempunyai suatu potongan tambahan yang sesuai dengan anatomi tubuh
EP1357940A4 (en) HEPATITIS? B? VIRUS THERAPY
PL364171A1 (en) Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics
GB9912639D0 (en) Improvements in and relating to treatment of respiratory conditions
BR9706938A (pt) Composto uso do mesmo formulação farmacêutica e processos para produzir o composto e para o tratamento ou a prevenção de sintomas ou efeitos de uma infecção virótica em um mamífero infectado incluindo um humano
EE200300502A (et) Katioonsete dekstraani derivaatide kasutamine annust piiravate elundite kaitsmiseks
EG21720A (en) Elastic member and disposable garment having improved fitness to body during entire use
PT948967E (pt) Tratamento de doencas virais em suicos
ATE223725T1 (de) Pflanzliches antivirales mittel
IT1319128B1 (it) Procedimento e dispositivo per prelevare tipo di conducente
ITMI913493A1 (it) Dispositivo per la disinfezione o la immunizzazione di zone del corpo umano esposte al contagio, da germi, batteri e virus
NO20041685L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons
PL363175A1 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
DE59810175D1 (de) Physiologische wirkstoffkombination zur förderung der abwehrleistungen der haut gegenüber noxen
NO970185D0 (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
NO20022393D0 (no) Behandling av hjerterytmeforstyrrelser med N6-substituerte-5'- (N-substituerte)-karboksamidoadenosiner